- Home
- EMD vs CTNM Comparison
EMD vs CTNM Comparison
Compare EMD & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | EMD | CTNM |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 609.8M | 550.7M |
| IPO Year | 2003 | 2024 |
Fundamental Metrics
Financial Performance| Metric | EMD | CTNM |
|---|---|---|
| Price | $9.45 | $7.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $22.14 |
| AVG Volume (30 Days) | 255.9K | ★ 1.2M |
| Earning Date | 01-01-0001 | 10-29-2026 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.10 | $7.72 |
| 52 Week High | $11.30 | $17.79 |
Technical Indicators
Market Signals| Indicator | EMD | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 43.87 | 22.34 |
| Support Level | $9.10 | N/A |
| Resistance Level | $10.71 | $14.22 |
| Average True Range (ATR) | 0.18 | 1.15 |
| MACD | 0.04 | -0.52 |
| Stochastic Oscillator | 55.37 | 3.33 |
Price Performance
Historical ComparisonAbout EMD Western Asset Emerging Markets Debt Fund Inc
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management and long term investment company. The primary investment objective of the company is to seek high current income, and the secondary objective is to seek capital appreciation.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.